rhTSH, Thyroid Size, and Radioiodine Therapy in Benign Goiter
Benign Nontoxic and Toxic Goiter, Graves' Disease
About this trial
This is an interventional treatment trial for Benign Nontoxic and Toxic Goiter focused on measuring Benign nontoxic and toxic goiter, rhTSH, 131I, goiter reduction, 131I kinetic, thyroid size, patient satisfaction, adverse effects, BRT, Graves' disease
Eligibility Criteria
Inclusion Criteria: Healthy volunteers with an intact thyroid gland Patients with nontoxic/subtoxic nodular goiter confirmed by ultrasonography Patients with toxic nodular goiter Patients with Graves' disease Exclusion Criteria: Treatment with drugs that alter thyroid function or size (the last 3 months prior to inclusion) Prior 131I treatment Alcohol, medicine or drug abuse Pregnancy or lactation No safe contraception Participation in another clinical trial Allergic reaction towards rhTSH Fine needle biopsy without valid diagnostic criteria for benign disease Suspicion of malignancy, increased ionized serum calcium and/or serum calcitonin Incontinence Physically or psychic condition that hinders corporation Ischemic attack up till 3 months before inclusion
Sites / Locations
- Department of Endocrinology, Odense University Hospital